Clinical trials: SARS CoV 2 Infection
Covid19
Study to Select the Dose and Evaluate Safety and Efficacy of Monoclonal Antibody in Adult With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19.
MAD0004J08, the experimental drug, is a potent neutralizing IgG1 monoclonal antibody (mAb) targeting the spike protein of SARS-CoV-2. MAD0004J08 blocks viral attachment and entry into human cells and neutralizes the virus.
- Trial name
- NCT04952805
- Testing
- MAD0004J08
- Where
- 14 sites in Italy
- Volunteers
- 800 people
- Sponsor
- Toscana Life Sciences Sviluppo s.r.l.
COVID-19
Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)
This study is a randomized and controlled Phase IV clinical trial of the COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05107557
- Testing
- Experimental Group
- Where
- 2 sites in China
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Mild to Moderate COVID-19
JT001 (VV116) for the Early Treatment of COVID-19
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of JT001 (VV116) for the early Treatment of Coronavirus Disease 2019 (COVID-19) in participants with mild to moderate COVID-19, at high risk for…
- Trial name
- NCT05242042
- Testing
- JT001
- Where
- 8 sites in China, Hong Kong
- Volunteers
- 381 people
- Sponsor
- Shanghai JunTop Biosciences Co., LTD
COVID-19 Pneumonia
Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19
This study is being done to determine the highest tolerated dose of an investigational cell therapy called DVX201 in patients hospitalized with COVID-19. DVX201 is an allogeneic NK (natural killer) cell therapy.
- Trial name
- NCT04900454
- Testing
- DVX201
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Coeptis Therapeutics
Covid19
To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants
This is a randomized (1:1), double-blind, placebo-controlled phase 2 study to assess safety and efficacy of Total TQ Formula (3 g daily dose of Nigella Sativa Oil) capsules versus placebo in treating patients who have tested…
- Trial name
- BOSS (NCT04914377)
- Testing
- TQ Formula/Tab
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Novatek Pharmaceuticals
COVID-19
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TD0069 Capsule for Patients With Mild to Moderate COVID-19
The acute pneumonia pandemic caused by a new strain of corona virus 2019, namely as COVID-19 by the World Health Organization (WHO), is a pandemic caused by SARS-CoV-2 virus.
- Trial name
- NCT05249777
- Testing
- TD0069 hard capsule
- Where
- 2 sites in Vietnam
- Volunteers
- 573 people
- Sponsor
- Sao Thai Duong Joint Stock Company
COVID-19
Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults
This study is a double-blind, randomized phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine (CoronaVac）manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04894227
- Testing
- Inactivated SARS-CoV-2 Vaccine (Vero cell）
- Where
- China
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19
This is a phase 2 randomized, double-blind clinical trial testing an anti-SARS-CoV-2 COVID-19 vaccine (AV-COVID-19) made on site using PT AIVITA Biomedika Indonesia's vaccine-enabling kit for the prevention of COVID-19 infection.
- Trial name
- NCT05007496
- Testing
- AV-COVID-19
- Where
- Indonesia
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Aivita Biomedical, Inc.
COVID-19
Booster Study of SpikoGen COVID-19 Vaccine
The purpose of the study is to assess the effectiveness of Spikogen vaccine when used as a 3rd or 4th dose booster in adults who have been previously vaccinated with any Covid-19 vaccine types, including mRNA vaccine, adenoviral…
- Trial name
- NCT05542862
- Testing
- SpikoGen vaccine
- Where
- Australia
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Arbovirus Disease, Zika
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
The Pacific region is facing several emerging and neglected diseases notably mosquito-borne diseases as malaria or arboviroses among which dengue, Ross River, chikungunya and Zika.
- Conditions
- Arbovirus Disease, Zika, Dengue, Ross River
- Trial name
- PIANO (NCT05153018)
- Testing
- Blood collection
- Where
- 4 sites in Vanuatu
- Volunteers
- 1,122 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID-19, SARS-CoV-2
NOWDx Test for the Detection of Antibodies to COVID-19
This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device.
- Conditions
- COVID-19, SARS-CoV-2, Coronavirus
- Trial name
- NCT04690413
- Testing
- NOWDx COVID-19 Test
- Where
- 3 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- NOWDiagnostics, Inc.
COVID-19
The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2
Clinical trial on safety and efficacy of KIN001 in non-hospitalized patients with COVID-19.
- Trial name
- KIN-FAST (NCT05659459)
- Testing
- KIN001
- Where
- 8 sites in Germany, Switzerland
- Volunteers
- 17 people
- Sponsor
- Kinarus AG
Respiratory Infection Virus, COVID-19
Noseguard for Prevention of Respiratory Infections in Real-World Use
This study is a prospective clinical study to evaluate the effectiveness of combined use of two nasal protective medical devices (Noseguard and Noseguard Night) in reducing respiratory infection rates, including COVID-19 and…
- Conditions
- Respiratory Infection Virus, COVID-19, Influenza
- Trial name
- NCT07516977
- Testing
- Noseguard and Noseguard Night
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Coronavirus Disease
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults
The purpose of this study is to assess safety, tolerability, preliminary efficacy, and PK of TAK-671 in participants with COVID-19.
- Trial name
- NCT04464460
- Testing
- TAK-671
- Sponsor
- Takeda
Covid19
A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects
This will be an open label, prospective, multi-center, comparative, interventional study to evaluate safety and efficacy of Artemisinin 500 mg in subjects with mild to moderate COVID-19.
- Trial name
- NCT05004753
- Testing
- Artemisinin, Dexamethasone
- Where
- 3 sites in India
- Volunteers
- 120 people
- Sponsor
- Mateon Therapeutics
COVID-19
A Comparison of Sample Collection Methods for SARS-COV-2 Antibody Testing
The negative global consequences of the COVID-19 pandemic has prompted efforts to develop efficient laboratory testing protocols that can be quickly scaled in a practical way.
- Trial name
- NCT04537572
- Testing
- comparison of sample collection methods
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Salveo Diagnostics
COVID-19
The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19
The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 150 mg versus placebo once daily administration with standard of care therapy for 10 days in patients with mild and moderate COVID-19.
- Trial name
- NCT04891302
- Testing
- Clevudine
- Where
- 11 sites in South Korea
- Volunteers
- 104 people
- Sponsor
- Bukwang Pharmaceutical
COVID-19, SARS-CoV-2
A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2
- Trial name
- NCT06039449
- Testing
- VYD222 (pemivibart), Normal saline
- Where
- 18 sites in United States
- Volunteers
- 790 people
- Sponsor
- Invivyd, Inc.
Influenza, Human, SARS-CoV-2 Infection
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the…
- Conditions
- Influenza, Human, SARS-CoV-2 Infection, COVID-19
- Trial name
- NCT06237049
- Testing
- BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV
- Where
- 30 sites in United States
- Volunteers
- 644 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Effectiveness of Chinese COVID-19 Vaccines in Latin America and the Caribbean
This multi-country study seeks to collect real-world evidence (RWE), from Latin American and Caribbean countries, on the effectiveness of China-made COVID-19 vaccines in different populations, against different clinical outcomes…
- Trial name
- NCT05475704
- Where
- 5 sites in Argentina, Colombia and 2 more
- Volunteers
- 59 people
- Sponsor
- P95